Julie M Gastier-Foster
Overview
Explore the profile of Julie M Gastier-Foster including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
7518
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chirande L, Chirande L, Namazzi R, Hockenberry M, Wasswa P, Kiguli S, et al.
Blood Adv
. 2024 Dec;
9(4):939-947.
PMID: 39631074
The spectrum of hematological diseases in African children includes anemias, bleeding disorders, thromboses, and oncological diseases such as leukemias. Although data are limited, outcomes for these diseases are poorer in...
2.
Gastier-Foster J, Lutwama F, Mbabazi O, Mlenga S, Ulaya K, Namazzi R, et al.
Front Oncol
. 2024 Jun;
14:1426638.
PMID: 38939333
Risk stratification and molecular targeting have been key to increasing cure rates for pediatric cancers in high-income countries. In contrast, precise diagnosis in low-resource settings is hindered by insufficient pathology...
3.
Morton L, Lee O, Karyadi D, Bogdanova T, Stewart C, Hartley S, et al.
Nat Commun
. 2024 Jun;
15(1):5053.
PMID: 38871684
Childhood radioactive iodine exposure from the Chornobyl accident increased papillary thyroid carcinoma (PTC) risk. While cervical lymph node metastases (cLNM) are well-recognized in pediatric PTC, the PTC metastatic process and...
4.
Brownlee A, Dewey M, Chagomerana M, Tomoka T, Mulenga M, Khan S, et al.
Front Med (Lausanne)
. 2024 Feb;
11:1336861.
PMID: 38298817
The pathology laboratory at Kamuzu Central Hospital (KCH) in Lilongwe, Malawi was established in 2011. We published our initial experiences in laboratory development and telepathology in 2013 and 2016, respectively....
5.
Rabin K, Devidas M, Chen Z, Ji L, Kairalla J, Hitzler J, et al.
J Clin Oncol
. 2023 Oct;
42(2):218-227.
PMID: 37890117
Purpose: Patients with Down syndrome (DS) and B-ALL experience increased rates of relapse, toxicity, and death. We report results for patients with DS B-ALL enrolled on Children's Oncology Group trials...
6.
Lubega J, Chirande L, Atwine B, Davidson A, Kashaigili H, Kanyamuhunga A, et al.
Lancet Oncol
. 2023 Jul;
24(7):729-732.
PMID: 37414010
No abstract available.
7.
Hunger S, Tran T, Saha V, Devidas M, Valsecchi M, Gastier-Foster J, et al.
Lancet Haematol
. 2023 Jul;
10(7):e510-e520.
PMID: 37407142
Background: The outcome of children with Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukaemia significantly improved with the combination of imatinib and intensive chemotherapy. We aimed to investigate the efficacy of dasatinib,...
8.
Thomas N, Dreval K, Gerhard D, Hilton L, Abramson J, Ambinder R, et al.
Blood
. 2022 Oct;
141(8):904-916.
PMID: 36201743
Burkitt lymphoma (BL) accounts for most pediatric non-Hodgkin lymphomas, being less common but significantly more lethal when diagnosed in adults. Much of the knowledge of the genetics of BL thus...
9.
Reglero C, Dieck C, Zask A, Forouhar F, Laurent A, Lin W, et al.
Cancer Discov
. 2022 Aug;
12(11):2646-2665.
PMID: 35984649
Significance: Relapse-associated NT5C2 mutations directly contribute to relapse in ALL by driving resistance to chemotherapy with 6-MP. Pharmacologic inhibition of NT5C2 with CRCD2, a first-in-class nucleotidase inhibitor, enhances the cytotoxic...
10.
Taylor A, Sun J, Yu A, Voicu H, Shen J, Barkauskas D, et al.
Int J Mol Sci
. 2022 Jul;
23(14).
PMID: 35887382
Osteosarcoma is a primary malignant bone tumor arising from bone-forming mesenchymal cells in children and adolescents. Despite efforts to understand the biology of the disease and identify novel therapeutics, the...